The European Innovative Medicines Initiative: Progress to Date
- PDF / 760,148 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 84 Downloads / 165 Views
LEADING ARTICLE
The European Innovative Medicines Initiative: Progress to Date Jean‑Emmanuel Faure1 · Tomasz Dyląg1 · Irene Norstedt1 · Line Matthiessen1 Published online: 19 July 2018 © The Author(s) 2018
Abstract The Innovative Medicines Initiative is a public–private partnership between the European Union and the pharmaceuticals industry that was established in 2008, with an overall budget of €5.3 billion from 2008 until 2024. The objective of the initiative is to boost pharmaceutical innovation in Europe and speed up the development of innovative medicines, vaccines and medical technologies, in particular in areas with high unmet needs. This article discusses the objectives of the initiative, its governance and main results and impact. The initiative has proved to be a unique platform for multi-stakeholder collaborations across Europe. It has contributed to the acceleration of the development process for medicines, from drug discovery to clinical development. The initiative has made important steps towards accessing and using real-world evidence for pharmaceutical research and development, and for healthcare decision-making. Several projects have contributed to a better understanding of the causes of diseases, and some are already delivering results, such as a vaccine against Ebola virus. The initiative has also significantly contributed to building capacity and resources for open use by the broader research and innovation community.
Key Points
1 Rationale
The Innovative Medicines Initiative aims at boosting pharmaceutical innovation in Europe and ultimately improving health by speeding up the development of innovative medicines, vaccines and medical technologies, particularly in areas where there is an unmet medical need.
Horizon 2020 is the European Union (EU) Framework Programme for funding research and innovation running from 2014 to 2020 [1]. Horizon 2020 is divided into three pillars that support “Excellent Science”, “Industrial Leadership” and “Societal Challenges”. One of the flagships under the first Societal Challenge for “Health, demographic change and well-being” is the Innovative Medicines Initiative (IMI) [2]. IMI is a Joint Undertaking between the EU and the European Federation of Pharmaceutical Industries Associations (EFPIA)—as well as other industries. It is the world’s largest public–private initiative for health research and innovation. The initiative aims at boosting pharmaceutical innovation in Europe and ultimately improving health by speeding up the development of innovative medicines, vaccines and medical technologies, particularly in areas where there is an unmet medical need. The migration of research investments of the pharmaceutical industry out of Europe was one of the drivers for setting up IMI earlier in 2008, under the previous EU Framework Programme for Research and Technological Development (FP7), running from 2007 to 2013. IMI supports collaborative research and innovation projects and builds networks of industrial and academic experts, including non-pharmaceutical indu
Data Loading...
